Todd C. Davis - 02 Jul 2025 Form 4 Insider Report for Pelthos Therapeutics Inc. (CHRO)

Role
Director
Signature
/s/ Todd C. Davis
Issuer symbol
CHRO
Transactions as of
02 Jul 2025
Net transactions value
$0
Form type
4
Filing time
07 Jul 2025, 21:43:40 UTC
Previous filing
03 Jul 2025
Next filing
08 Dec 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Todd C. Davis filed Form 4 for Pelthos Therapeutics Inc. (CHRO) on 07 Jul 2025."

Quick Takeaways

  • This page summarizes Todd C. Davis's Form 4 filing for Pelthos Therapeutics Inc. (CHRO).
  • 2 reported transactions and 2 derivative rows are listed below.
  • Filing timestamp: 07 Jul 2025, 21:43.

What Changed

  • Previous filing in this sequence was filed on 03 Jul 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Davis Todd C Director C/O PELTHOS THERAPEUTICS INC., 4020 STIRRUP CREEK DRIVE, SUITE 110, DURHAM /s/ Todd C. Davis 07 Jul 2025 0001392029

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTHS Restricted Stock Units Award +19,108 +107% 36,969 02 Jul 2025 Common Stock 19,108 $13.50 Direct F1, F3
transaction PTHS Stock Option Award +58,230 58,230 02 Jul 2025 Common Stock 58,230 $13.50 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 2, 2025, the Reporting Person was granted restricted stock units to purchase 19,108 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.
F2 On July 2, 2025, the Reporting Person was granted stock options to purchase 58,230 shares of common stock at an exercise price of $13.50 per share, which shall vest on a quarterly basis over a period of three (3) years.
F3 The numbers reported herein have been adjusted to reflect the 1-for-10 reverse stock split effected by the Issuer on July 1, 2025.

Sponsored